8 May 2023 at 11h51 #4462Sarwa Darwish MuradParticipant
We have been asked to participate in a survey on DOACs in splanchnic vein thrombosis from the ISTH. Please see below for details.
If you can spare 10 minutes, please complete this survey.
Please paste the following link into your Internet browser:
If you have any questions, please contact Dr. Aurélien Delluc at firstname.lastname@example.org
Many thanks on behalf of Mandy Lauw (hematologist EMC) and the ISTH,
Dr S. (Sarwa) Darwish Murad MD, PhD
Gastroenterologist / Hepatologist
Gastroenterology and Hepatology
010 703 59 42 (secr.) | 06 28021137
From: Mandy Lauw <email@example.com>
Sent: maandag 17 april 2023 23:38
To: Sarwa Darwish Murad <firstname.lastname@example.org>
Subject: FW: SURVEY: Patterns of prescription of oral anticoagulants … for the treatment of DVT
From: ISTH <email@example.com>
Reply to: “firstname.lastname@example.org” <email@example.com>
Date: Monday, 17 April 2023 at 20:04
To: Mandy Lauw <firstname.lastname@example.org>
Subject: SURVEY: Patterns of prescription of oral anticoagulants … for the treatment of DVT
Anticoagulation is the mainstay of treatment for splanchnic vein thrombosis. Conventional anticoagulant options include unfractionated or low molecular weight heparin, eventually followed by vitamin K antagonists.
There is increasing evidence showing that direct oral anticoagulants (DOACs) are efficient and safe to treat splanchnic vein thrombosis for the initial 3 to 6 months. However, evidence is lacking on the optimal dose of long-term anticoagulation for secondary prevention after the initial treatment.
In this survey, we would like to find out whether and when you would consider DOAC dose reduction (i.e., apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) after the initial 3 to 6 months of treatment for symptomatic splanchnic vein thrombosis.
You are being asked to participate because you are a practicing physician expert in management of patients with SVT. It will take you approximately 10 minutes to complete this survey and we hope that you will be willing to answer all questions. All the answers will be kept anonymous, all data will be analyzed in aggregate form and cannot be traced back to individual participants.
Should you have any questions regarding this survey, please contact Dr. Aurélien Delluc at email@example.com
Thank you for participating!
Survey: Extended anticoagulation for secondary prevention of recurrent venous thromboembolism using low-dose direct oral anticoagulants in patients with splanchnic vein thrombosis
International Society on Thrombosis and Haemostasis
610 Jones Ferry Rd., Ste 205, Carrboro, NC 27510 USA | +1 919 929 3807 | firstname.lastname@example.org
- You must be logged in to reply to this topic.